
Lipid screening is a key component of risk assessment for primary prevention of atherosclerotic cardiovascular disease (ASCVD). More than one-quarter of Canadians with high cholesterol do not know that they have unhealthy lipid levels.
On April 10, the Canadian Cardiovascular Society (CCS) launched a national lipid screening awareness campaign to encourage people at risk of ASCVD to get their cholesterol, triglycerides, and Lp(a) levels tested and seek support from their healthcare provider. Digital ads are driving people who are at risk to a self-management tool that helps them understand and track their lipid test results, while ongoing social media posts, e-newsletters, and CCS stakeholder engagement activities are further disseminating the campaign’s key messages and reach.
Kindly support this campaign by:
- Using the updated Framingham Risk Score (FRS) calculator, available in digital and printable versions here and on the iCCS app.
- Sharing our new self-management resources about cholesterol testing and the Portfolio Diet with people at risk of ASCVD to help them manage high cholesterol.
- Joining the Management of Dyslipidemia in Primary Prevention accredited webinar on April 17, 2024, from 8:00 to 9:00 p.m. ET.
- Spreading our campaign messaging across social media, using our convenient toolkit.
Lastly, support the campaign by reviewing the 2021 CCS Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. They support meaningful conversation and shared decision-making between patient and healthcare provider, so that individual care plans can be made for risk screening, assessment, and treatment. The 2021 CCS Guidelines recommend that lipid screening include total cholesterol (TC), LDL-C, HDL-C, non-HDL-C, triglycerides (TG), as well as once in a lifetime lipoprotein(a) [Lp(a)] measurement and optional assessment of ApoB as part of a comprehensive risk assessment of ASCVD.
Other News
See AllNew: Focused Update of the Guidelines for the Use of Antiplatelet Therapy
February 29, 2024
Under the co-chair leadership of Drs. Kevin R. Bainey and Guillaume Marquis-Gravel, the Canadian...
Antiplatelet Therapy ASCVD GuidelinesNew: The CCS/CHFS 2023 Focused Clinical Practice Update of Patients With Differing Heart Failure Phenotypes
August 8, 2023
In this clinical practice update (CPU) we aim to provide responses to fundamental questions that...
Guidelines Heart failure PhenotypesNEW: Guidelines & KT Tools... Plus a Sleek New Version of the iCCS App!
June 14, 2023
We are excited to officially launch a new resource called Guidelines & KT Tools, housed on the...
Guidelines iCCS KT Tools